ORKA
Oruka Therapeutics, Inc.
$69.89
+2.07%
$4.2B
No data for this timeframe.
Vol
Market Cap$4.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (95%)
Inst. Holders50 funds
Inst. Value$1.2B
Inst. Activity9 buys / 8 sells
Insider Activity0B / 13S
Insider Net $-$6.1M
SEC Reports10
Press Releases3
Recent Activity
Jun 12, 2026
Insider
Dambkowski Carl sold 12,583 shares
Director @ $70.11 ($882.2K)
Jun 11, 2026
SEC
Five mega-passive institutional investors (State Street, Fidelity, T. Rowe Price, Schwab, BofA) increased their ORKA hol
INST-CLUSTER — Impact 3/10
Jun 11, 2026
Insider
Dambkowski Carl sold 22,417 shares
Director @ $70.13 ($1.6M)
Jun 9, 2026
short_volume
Short Volume: ORKA — 74.2% short (0.4M / 0.6M)
Short: 438,542 | Exempt: 8,200 | TRF Vol: 590,758 | Short Ratio: 74.2% | Off-exchange volume (dark p
Jun 2, 2026
Insider
Dambkowski Carl was granted 9,136 shares
Director
Jun 1, 2026
SEC
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include i
8-K — Impact 7/10
May 22, 2026
SEC
Director Carl Dambkowski and SVP Arjun Agarwal executed derivative exercises and open-market sales, with total open-mark
CLUSTER — Impact 3/10
Inst.
Alyeska Investment Group, L.P. — ADD
184,863 shares ($9.1M)
Price Targets
$142.17
+103.4% upside
Strong Buy
Current $69.89
Low $100.00
Median $141.50
High $200.00
12 analysts
$100.00
$200.00
Analyst Ratings
9Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 14, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | UBS | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.50 ▲ +5.3% | $-0.67 — $-0.41 | -9% YoY | 9 |
| Next Q | $-0.51 ▲ +7.0% | $-0.73 — $-0.38 | 8% YoY | 9 |
| Current FY | $-2.04 ▲ +5.6% | $-2.77 — $-1.69 | -10% YoY | 9 |
| Next FY | $-2.46 ▲ +4.6% | $-4.12 — $-1.37 | -21% YoY | 9 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (State Street, Fidelity, T. Rowe Price, Schwab, BofA) increased their ORKA hol
Jun 11, 2026
BULLISH
8-K
7/10
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include i
Jun 1, 2026
BEARISH
Press
6/10
Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising ap
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $364.5M | ADD |
| BlackRock, Inc. | $173.0M | ADD |
| RTW INVESTMENTS, LP | $101.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $91.2M | — |
| STATE STREET CORP | $79.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | Dambkowski Carl | SELL | $882.2K |
| Jun 11, 2026 | Dambkowski Carl | SELL | $1.6M |
| Jun 2, 2026 | Dambkowski Carl | A | $0.00 |
| Jun 2, 2026 | Kulkarni Samarth | A | $0.00 |
| Jun 2, 2026 | Martin Christopher | A | $0.00 |
50 institutional holders with $1.2B total value (23,844,214 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, RTW. Net buying activity: 9 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 7,431,403 | $364.5M | 31.2% | ADD +29.2% |
| 2 | BlackRock, Inc. | 3,527,087 | $173.0M | 14.8% | ADD +60.6% |
| 3 | RTW INVESTMENTS, LP | 2,058,148 | $101.0M | 8.6% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,859,631 | $91.2M | 7.8% | — |
| 5 | STATE STREET CORP | 1,613,461 | $79.1M | 6.8% | ADD +41.5% |
| 6 | Polar Capital Holdings Plc | 1,047,693 | $51.4M | 4.4% | — |
| 7 | CITADEL ADVISORS LLC | 1,007,537 | $49.4M | 4.2% | — |
| 8 | FRANKLIN RESOURCES INC | 1,004,056 | $49.2M | 4.2% | ADD +40.6% |
| 9 | Woodline Partners LP | 574,882 | $28.2M | 2.4% | ADD +46.9% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 350,892 | $17.2M | 1.5% | — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 321,949 | $15.8M | 1.4% | ADD +33.4% |
| 12 | VANGUARD FIDUCIARY TRUST CO | 257,071 | $12.6M | 1.1% | — |
| 13 | GOLDMAN SACHS GROUP INC | 246,711 | $12.1M | 1.0% | — |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 190,030 | $9.3M | 0.8% | — |
| 15 | Holocene Advisors, LP | 185,513 | $9.1M | 0.8% | — |
| 16 | Alyeska Investment Group, L.P. | 184,863 | $9.1M | 0.8% | ADD +84.9% |
| 17 | JENNISON ASSOCIATES LLC | 176,680 | $8.7M | 0.7% | — |
| 18 | MORGAN STANLEY | 175,454 | $8.6M | 0.7% | ADD +43.6% |
| 19 | DEUTSCHE BANK AG\ | 140,789 | $6.9M | 0.6% | — |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 121,225 | $5.9M | 0.5% | ADD +43.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | ADD | 100,000 | 184,863 | +84.9% | $9.1M | 2026-Q1 |
| MORGAN STANLEY | ADD | 122,198 | 175,454 | +43.6% | $8.6M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 84,716 | 121,225 | +43.1% | $5.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 139,272 | 100,091 | -28.1% | $4.9M | 2026-Q1 |
| Invesco Ltd. | TRIM | 143,121 | 97,042 | -32.2% | $4.8M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 42,503 | 66,600 | +56.7% | $3.3M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 3,041 | 45,459 | +1394.9% | $2.2M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 15,247 | 23,667 | +55.2% | $1.2M | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 9,676 | 22,840 | +136.0% | $1.1M | 2026-Q1 |
| Allianz Asset Management GmbH | TRIM | 10,300 | 7,100 | -31.1% | $348.3K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 1,450 | 3,186 | +119.7% | $156.3K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 1,302 | 719 | -44.8% | $35.3K | 2026-Q1 |
| CWM, LLC | TRIM | 586 | 424 | -27.6% | $20.8K | 2026-Q1 |
| Allworth Financial LP | ADD | 114 | 205 | +79.8% | $10.1K | 2026-Q1 |
| Avoro Capital Advisors LLC | EXIT | 1,333,340 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 600,000 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Blackstone Inc. | EXIT | 1,165,408 | 0 | -100.0% | $0.00 | 2026-Q1 |
| BlackRock, Inc. | ADD | 2,204,551 | 3,539,415 | +60.6% | $107.3M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 1,776,665 | 2,453,530 | +38.1% | $74.4M | 2025-Q4 |
| STATE STREET CORP | ADD | 652,028 | 1,383,847 | +41.5% | $41.9M | 2025-Q4 |
| Blackstone Inc. | ADD | 850,400 | 1,165,408 | +37.0% | $35.3M | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 1,037,002 | 600,000 | -42.1% | $18.2M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 246,926 | 329,496 | +33.4% | $10.0M | 2025-Q4 |
| Invesco Ltd. | DOUBLED | 16,318 | 143,121 | +777.1% | $4.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 78,995 | 139,272 | +76.3% | $4.2M | 2025-Q4 |
10 unique insiders with 27 transactions. Net insider value: -$6.1M ($0.00 bought, $6.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Dambkowski Carl | Director | SELL | 12,583 | $70.11 | $882.2K |
| Jun 11, 2026 | Dambkowski Carl | Director | SELL | 22,417 | $70.13 | $1.6M |
| Jun 2, 2026 | Dambkowski Carl | Director | AWARD | 9,136 | — | — |
| Jun 2, 2026 | Kulkarni Samarth | Director | AWARD | 9,136 | — | — |
| Jun 2, 2026 | Martin Christopher Nathan | Director | AWARD | 9,136 | — | — |
| Jun 2, 2026 | BALL KRISTINE M | Director | AWARD | 9,136 | — | — |
| Jun 2, 2026 | Fairmount Funds Management LLC | Director | AWARD | 9,136 | — | — |
| May 21, 2026 | Dambkowski Carl | Director | EXERCISE | 38,689 | $6.84 | $264.6K |
| May 21, 2026 | Dambkowski Carl | Director | SELL | 38,318 | $58.43 | $2.2M |
| May 21, 2026 | Dambkowski Carl | Director | EXERCISE | 11,904 | — | — |
| May 18, 2026 | Agarwal Arjun | Senior Vice President, Finance | EXERCISE | 2,000 | $12.50 | $25.0K |
| May 18, 2026 | Agarwal Arjun | Senior Vice President, Finance | SELL | 4,190 | $58.34 | $244.5K |
| May 15, 2026 | Goncalves Joana | Chief Medical Officer | EXERCISE | 3,500 | $6.84 | $23.9K |
| May 15, 2026 | Goncalves Joana | Chief Medical Officer | SELL | 4,800 | $61.56 | $295.5K |
| May 1, 2026 | Sandler Laura Lee | Chief Operating Officer | EXERCISE | 5,000 | $7.80 | $39.0K |
| May 1, 2026 | Sandler Laura Lee | Chief Operating Officer | SELL | 2,200 | $62.58 | $137.7K |
| Apr 15, 2026 | Goncalves Joana | Chief Medical Officer | EXERCISE | 3,500 | $6.84 | $23.9K |
| Apr 15, 2026 | Goncalves Joana | Chief Medical Officer | SELL | 4,227 | $65.73 | $277.8K |
| Mar 16, 2026 | Goncalves Joana | Chief Medical Officer | SELL | 2,921 | $40.11 | $117.2K |
| Mar 16, 2026 | Quinlan Paul T | General Counsel | SELL | 733 | $41.30 | $30.3K |
| Mar 16, 2026 | Klein Lawrence Otto | Chief Executive Officer | SELL | 1,729 | $41.30 | $71.4K |
| Mar 16, 2026 | Goncalves Joana | Chief Medical Officer | EXERCISE | 3,500 | $6.84 | $23.9K |
| Mar 16, 2026 | Sandler Laura Lee | Chief Operating Officer | SELL | 600 | $41.30 | $24.8K |
| Mar 16, 2026 | Agarwal Arjun | Senior Vice President, Finance | SELL | 395 | $41.30 | $16.3K |
| Mar 2, 2026 | Sandler Laura Lee | Chief Operating Officer | EXERCISE | 5,000 | $7.80 | $39.0K |
| Feb 17, 2026 | Goncalves Joana | Chief Medical Officer | EXERCISE | 3,500 | $6.84 | $23.9K |
| Feb 17, 2026 | Goncalves Joana | Chief Medical Officer | SELL | 6,064 | $32.30 | $195.9K |
10 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 6 neutral. Avg impact: 4.5/10.
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (State Street, Fidelity, T. Rowe Price, Schwab, BofA) incr
Jun 11, 2026
BULLISH
8-K
7/10
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field
Jun 1, 2026
NEUTRAL
CLUSTER
3/10
Director Carl Dambkowski and SVP Arjun Agarwal executed derivative exercises and open-market sales,
May 22, 2026
NEUTRAL
CLUSTER
3/10
Two senior insiders at Oruka Therapeutics (CMO & SVP Finance) collectively sold ~$540K of stock on M
May 18, 2026
BEARISH
424B5
7/10
Oruka Therapeutics filed two preliminary prospectus supplements for a combined equity offering of at
Apr 27, 2026
BULLISH
8-K
8/10
Oruka Therapeutics announced positive Phase 2a trial results for its anti-IL-23 antibody ORKA-001 in
Apr 27, 2026
NEUTRAL
DEFA14A
3/10
Oruka Therapeutics, Inc. (ORKA) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual
Apr 17, 2026
NEUTRAL
144
3/10
Joana Goncalves, an officer of Oruka Therapeutics, filed a Form 144 to notify intent to sell up to 2
Apr 15, 2026
NEUTRAL
EFFECT
3/10
Oruka Therapeutics' $1 billion shelf registration (S-3) has become effective, allowing the company t
Apr 13, 2026
BEARISH
CLUSTER
5/10
Multiple Oruka Therapeutics executives, including the CEO, CMO, and COO, sold shares in a coordinate
Mar 17, 2026
BEARISH
6/10
Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 p
Apr 28, 2026
BEARISH
6/10
Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded war
Apr 27, 2026
NEUTRAL
5/10
Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479
Mar 12, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 9 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$142.17 mean target
+103.4% upside
Strong Buy (1.15)
$100.00 Low
$200.00 High
| Metric | Value |
|---|---|
| Current Price | $69.89 |
| Target Low | $100.00 |
| Target Mean | $142.17 |
| Target Median | $141.50 |
| Target High | $200.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.15) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.50 | $-0.67 | $-0.41 | -8.8% | +5.3% | 7↑ 2↓ | $0.0B | 0.0% | 9 |
| Next Q 2026-09-30 |
$-0.51 | $-0.73 | $-0.38 | 7.9% | +7.0% | 8↑ 1↓ | $0.0B | 0.0% | 9 |
| Current FY 2026-12-31 |
$-2.04 | $-2.77 | $-1.69 | -10.1% | +5.6% | 8↑ 1↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-2.46 | $-4.12 | $-1.37 | -20.9% | +4.6% | 7↑ 1↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.500 | |
| 7d ago | $-0.500 | |
| 30d ago | $-0.528 | +0.028 |
| 60d ago | $-0.542 | +0.042 |
| 90d ago | $-0.658 | +0.158 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 13, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Apr 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Apr 7, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 13, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 13, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Mar 13, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 13, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 12, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
| Dec 18, 2025 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 9 | 10 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 9 | 9 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: ORKA — 74.2% short (0.4M / 0.6M)
Short: 438,542 | Exempt: 8,200 | TRF Vol: 590,758 | Short Ratio: 74.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: ORKA — 67.5% short (0.4M / 0.6M)
Short: 429,070 | Exempt: 2,542 | TRF Vol: 636,126 | Short Ratio: 67.5% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: ORKA — 76.8% short (0.6M / 0.7M)
Short: 556,783 | Exempt: 1,267 | TRF Vol: 724,925 | Short Ratio: 76.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: ORKA — 57.4% short (0.3M / 0.5M)
Short: 312,784 | Exempt: 7,299 | TRF Vol: 544,952 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: ORKA — 55.5% short (0.3M / 0.5M)
Short: 291,658 | Exempt: 0 | TRF Vol: 525,636 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
earnings_calendar
ORKA Q1 2026 Earnings Scheduled — 2026-05-20
May 18, 2026
short_volume
Short Volume: ORKA — 62.9% short (0.5M / 0.8M)
Short: 511,817 | Exempt: 226 | TRF Vol: 813,453 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ORKA — 69.9% short (0.4M / 0.6M)
Short: 403,536 | Exempt: 9 | TRF Vol: 577,087 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: ORKA — 274,099 shares ($17.3M) failed to deliver
Settlement: 20260514, Price: $63.18, FTD Value: $17,317,574.82, ORUKA THERAPEUTICS INC COM
May 13, 2026
short_interest
FTD: ORKA — 290,428 shares ($18.8M) failed to deliver
Settlement: 20260513, Price: $64.65, FTD Value: $18,776,170.2, ORUKA THERAPEUTICS INC COM
May 12, 2026
short_interest
FTD: ORKA — 292,473 shares ($19.2M) failed to deliver
Settlement: 20260512, Price: $65.68, FTD Value: $19,209,626.64, ORUKA THERAPEUTICS INC COM
May 11, 2026
short_interest
FTD: ORKA — 291,322 shares ($18.8M) failed to deliver
Settlement: 20260511, Price: $64.59, FTD Value: $18,816,487.98, ORUKA THERAPEUTICS INC COM
May 8, 2026
short_interest
FTD: ORKA — 251,644 shares ($16.1M) failed to deliver
Settlement: 20260508, Price: $64.07, FTD Value: $16,122,831.08, ORUKA THERAPEUTICS INC COM
May 7, 2026
short_volume
Short Volume: ORKA — 67.4% short (0.5M / 0.7M)
Short: 491,281 | Exempt: 1,231 | TRF Vol: 729,293 | Short Ratio: 67.4% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_interest
FTD: ORKA — 537,968 shares ($37.5M) failed to deliver
Settlement: 20260507, Price: $69.79, FTD Value: $37,544,786.72, ORUKA THERAPEUTICS INC COM